text: A phase II study of isolated lung perfusion with melphalan followed by pulmonary metastatectomy in patients with resectable pulmonary metastases of colorectal carcinoma, soft tissue sarcoma and osteosarcoma
  ILUP-II
  resectable pulmonary metastases of colorectal carcinoma, soft tissue sarcoma and osteosarcoma
  To determine time to progression of the primary malignancy (locally advanced or metastatic) in patients treated with isolated lung perfusionwith mephalan followed by pulmonary metastatectomy.
  To determine pulmonary toxicity by pulmonary function testing due to melphalan using ILuP and pulmonary metastatectomy
  To determine overall survival in patients treated with ILuP with melphalan using ILuP followed by pulmonary metastatectomy
  To determine mephalan concentrations in lung and tumortissue, systemic arterial circulation, perfusate, pleural effusions and bronchial lavage and perform population pharmacokinetic analyses
  To assess pulmonary intravascular volume by using computed tomography and per-operative dilution method
  Cytologic/histologic proof or high clinical probability of pulmonary metastases of colorectal carcinoma, soft tissue sarcoma or osteosarcoma